Palisade Bio regains Nasdaq minimum bid price compliance; reports $133.3M cash

PALISADE BIO, INC.

Received Nasdaq compliance letter confirming regained bid price requirement; matter closed as of Oct 15, 2025.
Cash and cash equivalents approx. $133.3 million as of Oct 15, 2025.
Outstanding common shares: 133,002,572; pre-funded warrants for 73,271,424 shares.
No other material corporate updates provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.